Maaps

Buy with conviction, hold with patience, and let market noise work in your favor.

[Barchart @Barchart]

German Stock Market just formed a Golden Cross for the first time since December 2023 🚨 The last one sent German stocks soaring 53% over the next 2 years 📈📈

[andrewdudum @AndrewDudum]

From super helpful to superhuman. The implications for population health are transformative. There’s so much to be optimistic about.

[Jim Cramer @jimcramer]

Who murdered Bitcoin?

[Watcher.Guru @WatcherGuru]

JUST IN: Bitcoin crashes under $63,000

[Barchart @Barchart]

JUST IN 🚨: SpaceX $SPCX will IPO at $135/share, target a $1.75 Trillion valuation, and make 555,555,555 shares available

[Jim Cramer @jimcramer]

I'm not going to tell you the selling isn't exaggerated tonight in Broadcom and CrowdStrike. I will say that they were parabolic and the parabola stocks will be hurt as all of these deals get priced. Please watch the top of Mad Money tonight for more

[Wall St Engine @wallstengine]

$AVGO -13% AH

$NVDA CEO Jensen Huang:

[The Kobeissi Letter @KobeissiLetter]

BREAKING: The US and Iran are closing in on a deal that would extend their ceasefire by 60 days and lay the framework for discussions on Iran's nuclear program, mediators say.

Details include:

1. This would include a "gradual reopening" of the Strait of Hormuz

2. It would also include a commitment to discussing the "diluting or handing over" of Iran's highly enrich uranium

3. The US would ease its blockade of the Strait of Hormuz and agree to sanctions relief

4. The US would also begin a phased unfreezing of Iran's assets

Both sides are nearing a "memorandum of understanding" to extend a ceasefire.

[Michael Saylor @saylor]

The most interesting story in Bitcoin right now is the rise of $SATA in the credit markets and the embrace of $ASST by the equity capital markets.

[Filing Tracker @FilingTracker]

$PLTR CEO Alexander Karp filed to sell 397,744 shares for $54,109,929.02 ($136.04/share) - Unscheduled:

https://t.co/3fjSU7SZJO

[andrewdudum @AndrewDudum]

Yesterday, we raised $350M from a wide range of high-caliber institutional investors who believe in the long-term vision of what we’re building.

It was more than we set out to raise, and it tells me that the industry believes in the value of our model and the impact of our platform. Given the terms we received, it's clear that our investors are taking a high-conviction view of our strategy.

This offering was designed to keep us flexible and is structured to minimize dilution, while giving us an efficient way to scale aggressively, interest-free, across strategic areas: global growth, infrastructure, and AI-power customer tools.

All of that is how we’re positioning ourselves to keep growing this year and make progress towards our ambitious long-term targets. More than that, though, it is part of how we’ll help more people do a simple but life-changing thing: just feel great.

https://t.co/fhPtm0gA7Z

[Polymarket @Polymarket]

JUST IN: SpaceX reportedly plans to begin trading on the Nasdaq June 12th under the ticker $SPCX.

[The Earnings Correspondent @earnings_guy]

$DLO (DLocal) graph review before earnings today after close:

[andrewdudum @AndrewDudum]

2026 is proving to be a defining year at Hims & Hers. More and more, we are the partner people rely on for a simpler, more personal path to feeling great.

Our Q1 2026 results are now live and they make it clear that we aren’t just growing. We’re showing the world what happens when you focus on transforming what people believe is possible in healthcare.

Here’s what to know from today’s numbers:

- We’re building momentum in the US. There are more ways than ever for customers to start – and stay – with Hims & Hers. That’s driving momentum across all of our specialties, especially weight loss, where we’re seeing near-record adoption levels since March. Our strategic shift is paying off.

- Our global reach is multiplying our impact. As we expand globally, we’ll bring more data points into our ecosystem and extend the network effects of our platform. This isn’t just good for our customers. It’s good for our partners, too, who are starting to see the potential in a high-touch, personal platform experience designed to help customers stick to their treatment plans longer and achieve their goals better than with medication alone.

- We have deeper-than-ever relationships with our customers. We’re moving beyond simply responding to symptoms by investing in areas like diagnostics that make it easier for anyone to feel their best. We’re now a trusted, comprehensive health partner that’s helping customers proactively discover early signs of conditions that may not be symptomatic yet.

- Our platform is getting harder to replicate. Our technology and data infrastructure is getting more agile and more intelligent with tens of millions of customer touchpoints. We power the end-to-end customer experience, which means we’re constantly growing a closed-loop, proprietary data flywheel that we believe is unmatched.

I’ve never been more confident in the future of health – and I’ve never been more sure that we’re the ones building it.

More on this quarter’s results: https://t.co/O44El2nhen

Important info here:
https://t.co/nCW7KGtVNJ

https://t.co/0hfWRjJdgb

[Flow God @FL0WG0D]

$QS - $159K Call buyer

[Michael Saylor @saylor]

No More ₿ears

[andrewdudum @AndrewDudum]

Looking forward to kicking off Monday’s earnings call (as always!) with questions from the Hims & Hers community. Send yours to [email protected] this weekend and we’ll answer the most popular live.

[andrewdudum @AndrewDudum]

Now live: the first AI care agent from Hims & Hers.

Trying to decipher complex lab results can be confusing at best and scary at worst (and more often than not, it can take weeks). We’re cutting through that all-too-common experience and making it simple to understand your full health profile — biomarkers, trends, history, context — and how to improve it.

This is what is possible when you apply first principles thinking and a world-class engineering team, led by our CTO Mo Elshenawy, to some of healthcare’s biggest challenges.

More to come.

[Maaps @Nojaminv]

@TheRonnieVShow $CIFR is better bet then this stock considering the huge dilution which many people would have forgot, imo

[Watcher.Guru @WatcherGuru]

JUST IN: $2 trillion Morgan Stanley launches crypto trading on its E*Trade platform.